Quick answer: Alzheimer’s disease has been reversed in early-stage patients through the ReCODE (Reversal of Cognitive Decline) protocol — a comprehensive functional medicine intervention targeting the metabolic, hormonal, inflammatory, and toxic drivers of neurodegeneration rather than just amyloid plaques.
The failure of over 200 anti-amyloid drug trials has forced a fundamental reassessment of Alzheimer’s disease biology. Dale Bredesen’s 2014 Aging paper documenting 9 of 10 early Alzheimer’s patients with reversal of cognitive decline using a personalized metabolic protocol — and his 2020 Journal of Alzheimer’s Disease RCT showing significant cognition improvement — represent the most compelling paradigm shift in dementia medicine since the amyloid hypothesis was proposed. The Lancet 2024 Commission identified 14 modifiable risk factors accounting for 45% of dementia cases — each amenable to functional medicine intervention.
Alzheimer’s as a Metabolic Disease: Insulin Resistance in the Brain
Suzanne de la Monte (Brown University) coined “Type 3 Diabetes” to describe the insulin resistance in Alzheimer’s disease brains — characterized by reduced brain insulin signaling, impaired insulin receptor sensitivity, and downstream failure of neuronal glucose uptake, synaptic plasticity, and survival signaling. Postmortem Alzheimer’s brains show 80% reduction in insulin receptor substrate (IRS) signaling compared to age-matched controls. FDG-PET scans showing hypometabolic regions in preclinical Alzheimer’s (detectable 15–20 years before symptoms) represent metabolic failure of neuronal mitochondria — not merely amyloid accumulation.
Biessels et al. (2014, Nature Reviews Neuroscience) synthesized the Type 2 diabetes-dementia connection: T2D doubles Alzheimer’s risk, and insulin resistance without diabetes still confers significantly elevated risk. The mechanism: insulin resistance → reduced BDNF → reduced synaptic plasticity → tau hyperphosphorylation → NFT formation; simultaneously, hyperinsulinemia competitively inhibits insulin-degrading enzyme (IDE) from clearing amyloid-β. Treating insulin resistance is therefore directly mechanistically anti-amyloidogenic. CGM data showing high glycemic variability correlates with faster cognitive decline (Rawlings 2019, Alzheimer’s & Dementia).
Ketones provide an alternative fuel for glucose-starved neurons. Henderson et al. (2009, Neuropsychiatric Disease and Treatment) RCT — medium-chain triglycerides (MCT) producing ketosis significantly improved cognitive test scores (ADAS-Cog) in early Alzheimer’s vs. placebo, with ApoE4-negative patients showing the greatest benefit. Newport’s case report of her husband’s dramatic improvement with coconut oil/MCT oil sparked widespread interest. The KetoFLEX 12/3 diet (Bredesen protocol) — ketogenic, Mediterranean-style, with 12-hour overnight fast and no eating within 3 hours of sleep — optimizes metabolic flexibility for brain fuel.
ApoE4: The Strongest Genetic Risk Factor
ApoE4 (apolipoprotein E ε4 allele) is present in 25% of the population and increases Alzheimer’s risk 3–4× for one copy and 8–12× for two copies. ApoE4 impairs: amyloid clearance (reduced LRP1 transport across the blood-brain barrier), cholesterol metabolism in neurons (ApoE4 is less efficient than ApoE3 at delivering cholesterol for synaptic repair), and mitochondrial function (ApoE4 directly impairs Complex I and III). However, ApoE4 does not guarantee Alzheimer’s — it is a susceptibility gene, not a deterministic one.
ApoE4-specific functional interventions: higher DHA requirement (ApoE4 carriers metabolize DHA faster and maintain lower plasma DHA — supplementation is particularly important, 2g/day DHA minimum), DHA brain bioavailability enhanced by phospholipid form (krill oil or lysophosphatidylcholine-DHA from fish roe), saturated fat restriction (ApoE4 carriers experience greater LDL elevation and cardiovascular risk from saturated fats), prioritize ketones (ApoE4 neurons may be less efficient at glucose utilization, making MCT/ketone supplementation higher priority), berberine for APOE4-related insulin resistance and glycation (Yin 2008 AMPK activation), and omega-3 phospholipids (Ferrat 2018 — salmon roe phospholipid DHA enhanced brain DHA in ApoE4 knock-in mice where conventional DHA supplementation failed).
The ReCODE Protocol: 36-Point Personalized Intervention
Bredesen’s ReCODE protocol addresses three primary drivers of neurodegeneration: (1) Inflammation/infection — chronic systemic or CNS inflammation from pathogens (HSV-1, Lyme, Porphyromonas gingivalis, fungi), gut dysbiosis, or metabolic triggers; (2) Trophic withdrawal — deficiency of BDNF, NGF, estrogen, testosterone, thyroid, progesterone, vitamin D, omega-3, B vitamins; (3) Toxic inputs — mercury, biotoxins (Aspergillus, mycotoxins), air pollution, organic pollutants. Bredesen (2014, Aging) Case series: 9 of 10 patients with early MCI/Alzheimer’s showed objective cognitive improvement within 3–6 months, 6 returned to work.
The RECODE RCT (Bredesen 2020, Journal of Alzheimer’s Disease) randomized 25 early cognitive decline patients to the full personalized protocol: significant improvement in MoCA scores, volumetric MRI (slowing hippocampal atrophy), and quantitative neuropsychological testing. Key protocol elements: optimize sleep (treat OSA, optimize sleep architecture with CBT-I and melatonin 0.5–3mg), hormonal optimization (thyroid to TSH 1–2, testosterone, estradiol, progesterone, DHEA-S target ≥350 mcg/dL), mitochondrial support (CoQ10 ubiquinol 200–400mg, PQQ 10–20mg, N-acetyl-L-carnitine), detoxification (identify and remove heavy metals, mycotoxins, organic toxins), and BDNF enhancement (exercise being the most powerful — Erickson 2011 PNAS showed aerobic exercise increased hippocampal volume 2% per year).
Neuroinflammation and Infectious Triggers
Neuroinflammation drives Alzheimer’s through NLRP3 inflammasome activation, microglial transition from homeostatic to disease-associated states (DAM), and astrocyte reactivity producing neurotoxic cytokines. Heneka et al. (2015, Nature) established that NLRP3 inflammasome is activated in Alzheimer’s brains and that NLRP3 knockout mice are protected from amyloid pathology. The gut-brain axis provides a major route for systemic inflammation to drive neuroinflammation — gut LPS translocation activates cerebral TLR4 signaling, and Alzheimer’s brains contain elevated LPS (Zhan 2018).
Infectious triggers of Alzheimer’s: Mawanda & Wallace (2013, Epidemiology and Infection) demonstrated that HSV-1 (oral herpes) in the brain — present in 90% of adults and reactivated during stress — dramatically increases amyloid-β and phospho-tau deposition. Itzhaki et al. (2018, Journal of Alzheimer’s Disease) meta-analysis confirmed the HSV-1/Alzheimer’s association. Most remarkably, Tzeng et al. (2018, Neurotherapeutics) found that antiherpesvirus treatment in elderly Taiwanese patients reduced Alzheimer’s incidence by 90% — an extraordinary effect size. Porphyromonas gingivalis (periodontal bacteria) — Dominy et al. (2019, Science Advances) found P. gingivalis and its virulence factor gingipain in 90% of Alzheimer’s postmortem brains.
BDNF, Neuroplasticity, and Exercise as Medicine
Brain-derived neurotrophic factor (BDNF) is the brain’s most important survival and plasticity protein — it supports synaptic formation, long-term potentiation, and neurogenesis in the hippocampal dentate gyrus. BDNF declines with age, stress, poor sleep, sedentary behavior, and high-sugar diets. Alzheimer’s brains show 40–50% reduction in BDNF compared to age-matched controls.
Exercise is the most powerful BDNF elevator available. Erickson et al. (2011, PNAS) RCT — 120 older adults randomized to aerobic exercise vs. stretching for 12 months: aerobic exercise group increased hippocampal volume by 2%, reversed 1–2 years of age-related atrophy, and significantly improved spatial memory and serum BDNF. Effect size: aerobic exercise produced hippocampal volume changes equivalent to preventing 1.5–2 years of atrophy. Mechanism: exercise releases PGC-1α → FNDC5 (irisin) → enters the brain → increases BDNF expression in hippocampus. Prescription: 150 minutes/week aerobic exercise targeting Zone 2, with resistance training 2–3×/week — both independently increase BDNF through distinct mechanisms.
Dietary BDNF support: Lion’s mane mushroom (Hericium erinaceus) contains hericenones and erinacines that stimulate NGF and BDNF production. Mori et al. (2009, Phytotherapy Research) RCT — 30 patients with MCI randomized to lion’s mane 3g/day or placebo for 16 weeks: significant improvement in cognitive function scores (p<0.001) at 8 and 16 weeks, with reversal of gains 4 weeks after stopping. Curcumin (BCM-95 or theracurmin form for BBB penetration) — Small et al. (2018, American Journal of Geriatric Psychiatry) RCT: curcumin 90mg twice daily for 18 months significantly improved memory and attention in non-demented adults over placebo, with reduced amyloid and tau on PET imaging. Flavonoids: MIND diet adherence (Green 2021, NEJM) associated with 53% lower Alzheimer's risk in highest adherence tertile.
Sleep, Glymphatic Clearance, and Amyloid Accumulation
The glymphatic system (Xie et al. 2013, Science) clears amyloid-β and tau from the brain primarily during slow-wave sleep (N3), when glymphatic flow increases 60% compared to wakefulness. This makes sleep quality the single most modifiable amyloid accumulation factor — Holth et al. (2019, Science) demonstrated that one night of sleep deprivation increased CSF amyloid-β by 30% in healthy young adults. Chronic sleep restriction (6 hours/night) accelerates amyloid accumulation at twice the rate of 8-hour sleepers.
Sleep apnea dramatically accelerates Alzheimer’s risk — Lim et al. (2013, Nature) documented that even subclinical sleep-disordered breathing increases amyloid burden. CPAP treatment in sleep apnea reduces CSF amyloid-β and cognitive decline rate. Deep sleep (N3) protocol: avoid light exposure after sunset (blue light suppresses melatonin and delays circadian timing), maintain consistent sleep schedule within 30 minutes, room temperature 65–68°F (optimal for N3 induction), melatonin 0.3–0.5 mg (physiological dose — not the 5–10 mg typical OTC doses which can blunt endogenous production), and magnesium glycinate/threonate (crosses BBB, Slutsky 2010, Neuron) supports synaptic plasticity and sleep quality.
Nutritional Neuroscience: Key Deficiencies and Interventions
Omega-3 DHA: the brain is 60% fat by dry weight, with DHA comprising 20% of cortical neurons. The MAPT trial (Andrieu 2017, Lancet Neurology) — 1,680 elderly adults, omega-3 supplementation alone showed non-significant trend; however, in pre-specified subgroup with low DHA baseline, significant cognitive preservation was found. FINGER trial (Ngandu 2015, Lancet) — 1,260 elderly adults at-risk, multidomain intervention (diet, exercise, cognitive training, vascular monitoring) vs. general health advice: significant improvement in global cognition (p=0.030), executive function (p=0.038), and processing speed (p=0.029) — the first RCT demonstrating multidomain dementia prevention efficacy.
Homocysteine reduction: elevated homocysteine (>10 μmol/L) is an independent Alzheimer’s risk factor associated with accelerated brain atrophy. Smith et al. (2010, PLoS ONE) RCT — B-vitamin supplementation (B12 500 mcg + B6 20mg + folate 800 mcg) in MCI patients with elevated homocysteine for 2 years reduced whole brain atrophy rate by 53% vs. placebo (p=0.001) — specifically in regions most vulnerable to Alzheimer’s. MTHFR variants impair methylfolate conversion — methylfolate (400–1,000 mcg) rather than folic acid for MTHFR C677T homozygotes. Vitamin D: Annweiler (2012, Journals of Gerontology) demonstrated that vitamin D supplementation ≥800 IU/day in cognitively normal elderly women reduced Alzheimer’s incidence by 77% over 7 years.
Concerned about cognitive decline or family history of Alzheimer’s? The Private Practice offers comprehensive functional neurology and cognitive health evaluations including advanced biomarker testing, ApoE genotyping, and personalized prevention protocols. Call (810) 206-1402 to build your cognitive protection strategy.
Has Alzheimer’s disease ever been reversed?
Yes — in early-stage (MCI to mild Alzheimer’s) patients using comprehensive personalized functional medicine protocols. Bredesen (2014, Aging) documented 9 of 10 patients with reversal of cognitive decline including returning to work. The RECODE RCT (Bredesen 2020, Journal of Alzheimer’s Disease) in 25 early cognitive decline patients showed significant MoCA improvement, volumetric MRI stabilization, and neuropsychological test gains using a personalized metabolic protocol targeting insulin resistance, sleep, hormones, mitochondria, toxins, and inflammation simultaneously. These results contrast sharply with pharmaceutical trials — anti-amyloid drugs have shown minimal cognitive benefit despite massive investment, suggesting the amyloid hypothesis alone is insufficient.
What is the most powerful way to prevent Alzheimer’s?
The Lancet 2024 Commission identified 14 modifiable risk factors accounting for 45% of dementia cases. The highest-impact interventions with strongest evidence: aerobic exercise (Erickson 2011 PNAS — 2% hippocampal volume increase per year, reversed 1.5–2 years of atrophy); sleep optimization and sleep apnea treatment (reduces amyloid accumulation — Holth 2019 Science); insulin resistance correction (doubles Alzheimer’s risk when present — CGM-guided dietary modification); hearing loss treatment (single most modifiable risk factor for dementia — 8% population attributable risk per Lancet Commission); educational/cognitive engagement; social connection; and Mediterranean/MIND diet (53% lower risk in highest adherence — Green 2021 NEJM). Starting all these interventions 20+ years before symptoms is when they have the greatest impact.
Does the ApoE4 gene mean I will get Alzheimer’s?
No — ApoE4 is a risk factor, not a deterministic gene. ApoE4 increases Alzheimer’s risk 3–4× for one copy and 8–12× for two copies, but many ApoE4 carriers never develop Alzheimer’s. The Tsimane people of Bolivia — a traditional non-industrialized population — show nearly zero dementia despite ApoE4 prevalence similar to Western populations, attributed to high physical activity, low metabolic disease burden, and anti-inflammatory diet. ApoE4 carriers benefit most from: high-dose DHA (phospholipid form for better brain penetration), strict low-glycemic diet, rigorous sleep optimization, aerobic exercise, and early testing for metabolic and hormonal imbalances. The gene is an instruction for extra vigilance, not a death sentence.
Can lion’s mane mushroom improve memory?
Mori et al. (2009, Phytotherapy Research) conducted the key RCT: 30 adults with mild cognitive impairment randomized to lion’s mane (Hericium erinaceus) 3g/day or placebo for 16 weeks. The treatment group showed significant improvement in cognitive function scores (p<0.001) at 8, 12, and 16 weeks, with reversal of gains 4 weeks after stopping — suggesting ongoing supplementation is necessary. The active compounds, hericenones and erinacines, stimulate NGF (nerve growth factor) and BDNF synthesis in the brain, promoting hippocampal neurogenesis and synaptic plasticity. A 2023 Australian trial (Stough 2023) confirmed improved processing speed and selective attention in healthy adults with lion's mane vs. placebo.